Sarah A Morrow1, Heather Rosehart2. 1. Department of Clinical Neurological Sciences, London Health Sciences Center, Western University, LHSC-UH, 339 Windermere Road, London, ON, Canada, N5A 5A5. sarah.morrow@lhsc.on.ca. 2. Department of Clinical Neurological Sciences, London Health Sciences Center, Western University, LHSC-UH, 339 Windermere Road, London, ON, Canada, N5A 5A5.
Abstract
RATIONALE: Multiple sclerosis (MS) commonly affects cognitive function, most frequently presenting as impaired processing speed (PS). There are currently no approved treatments for PS in this population, but previous studies suggest amphetamines may be beneficial. OBJECTIVE: The objective of this study is to determine if mixed amphetamine salts, extended release (MAS-XR) has the potential to improve impaired PS in MS patients in a randomized controlled pre- and post-dose testing study. METHODS: Fifty-two MS patients demonstrating PS impairment on either the Symbol Digit Modalities Test (SDMT) or Paced Auditory Serial Addition Test (PASAT) were randomized to a single dose of 5 mg MAS-XR (n = 18), 10 mg MAS-XR (n = 20), or placebo (n = 14). Subjects were evaluated a second time, after taking the blinded medication. ANOVA was used to compare the change on the SDMT and PASAT in each of the treatment groups compared to the placebo. Cohen's d was used to calculate effect size. RESULTS: At baseline, the mean SDMT score was 43.3 ± 7.2 and the mean PASAT was 34.8 ± 13.4, with 47 (90.4 %) and 25 (48.1 %) categorized as impaired on the SDMT and PASAT, respectively. The change in SDMT scores from baseline to post-treatment demonstrated significant improvement for the MAS-XR 10-mg dose compared to placebo, increasing by 5.2 ± 4.5 vs. 0.6 ± 4.4 points (p = 0.043), with a medium effect size of 0.47. Change on the PASAT was not significantly different in either treatment group. CONCLUSIONS: This study supports MAS-XR 10 mg as a potential treatment for MS patients with demonstrated PS impairment, warranting a larger longitudinal study.
RCT Entities:
RATIONALE: Multiple sclerosis (MS) commonly affects cognitive function, most frequently presenting as impaired processing speed (PS). There are currently no approved treatments for PS in this population, but previous studies suggest amphetamines may be beneficial. OBJECTIVE: The objective of this study is to determine if mixed amphetamine salts, extended release (MAS-XR) has the potential to improve impaired PS in MSpatients in a randomized controlled pre- and post-dose testing study. METHODS: Fifty-two MSpatients demonstrating PS impairment on either the Symbol Digit Modalities Test (SDMT) or Paced Auditory Serial Addition Test (PASAT) were randomized to a single dose of 5 mg MAS-XR (n = 18), 10 mg MAS-XR (n = 20), or placebo (n = 14). Subjects were evaluated a second time, after taking the blinded medication. ANOVA was used to compare the change on the SDMT and PASAT in each of the treatment groups compared to the placebo. Cohen's d was used to calculate effect size. RESULTS: At baseline, the mean SDMT score was 43.3 ± 7.2 and the mean PASAT was 34.8 ± 13.4, with 47 (90.4 %) and 25 (48.1 %) categorized as impaired on the SDMT and PASAT, respectively. The change in SDMT scores from baseline to post-treatment demonstrated significant improvement for the MAS-XR 10-mg dose compared to placebo, increasing by 5.2 ± 4.5 vs. 0.6 ± 4.4 points (p = 0.043), with a medium effect size of 0.47. Change on the PASAT was not significantly different in either treatment group. CONCLUSIONS: This study supports MAS-XR 10 mg as a potential treatment for MSpatients with demonstrated PS impairment, warranting a larger longitudinal study.
Authors: K Gehring; S Y Patwardhan; R Collins; M D Groves; C J Etzel; C A Meyers; J S Wefel Journal: J Neurooncol Date: 2011-10-02 Impact factor: 4.130
Authors: Sarah A Morrow; Audrey Smerbeck; Kara Patrick; Diane Cookfair; Bianca Weinstock-Guttman; Ralph H B Benedict Journal: J Neurol Date: 2012-09-23 Impact factor: 4.849
Authors: R H B Benedict; J A Duquin; S Jurgensen; R A Rudick; J Feitcher; F E Munschauer; M A Panzara; B Weinstock-Guttman Journal: Mult Scler Date: 2008-06-23 Impact factor: 6.312
Authors: Brett A Parmenter; Robert Zivadinov; Laura Kerenyi; Rebecca Gavett; Bianca Weinstock-Guttman; Michael G Dwyer; Neeta Garg; Frederick Munschauer; Ralph H B Benedict Journal: J Clin Exp Neuropsychol Date: 2007-02 Impact factor: 2.475
Authors: Patrick C Dolder; Petra Strajhar; Patrick Vizeli; Alex Odermatt; Matthias E Liechti Journal: Psychopharmacology (Berl) Date: 2018-02-09 Impact factor: 4.530